Immunotherapy in the treatment of non-small cell lung cancer

Česká verzia

Authors: O. Bílek; S. Bořilová; P. Grell; I. Kiss
Authors place of work: Klinika komplexní onkologické péče LF MU a MOÚ Brno
Published in the journal: Klin Onkol 2021; 34(Supplementum 1): 54-64
Category: Review
doi: https://doi.org/10.48095/ccko2021S54

Summary

Immunotherapy with check-point inhibitors has demonstrated remarkable therapeutic benefits in many oncological diagnoses, including non-small cell lung cancer (NSCLC). Based on the data from clinical trials, it has become an important part of the NSCLC treatment algorithm. Treatment with programmed cell death protein 1 / programmed death-ligand 1 inhibitors can be indicated in various ways: as monotherapy or combination of immunotherapy with cytotoxic T-lymphocyte antigen 4 inhibitors or in combination with other treatment modalities – chemotherapy, antiangiogenic therapy and radiotherapy. Regarding new spectrum of immune-related side effects, which require quick diagnosis and treatment, there is great urge to identify immunotherapy predictive biomarkers.

Keywords:

Non-small cell lung cancer – immunotherapy – programmed cell death protein 1

Zdroje

1. Dušek L, Mužík J, Kubásek M et al. Epidemiologie zhoubných nádorů v České republice. [online]. Dostupné z: http: //www.svod.cz.

2. European Society for Medical Oncology. Metastatic non-small-cell lung cancer: ESMO Clinical Practoce Guidelines for diagnosis, treatment and follow-up. [online]. Available from: https: //www.esmo.org/content/download/227453/3874538/1

3. Bílek O, Bohovicová L, Demlová R et al. Non-small cell lung cancer – from immunobiology to immunotherapy.Klin Onkol 2016; 29 (Suppl 4): 78–87.

4. Lawrence MS, Stojanov P, Polak P et al. Mutational heterogeneity in cancer and the search for new cancer genes. Nature 2013; 499 (7457): 214–218. doi: 10.1038/nature12213.

5. https: //www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf.

6. Hodi FS, Ballinger M, Lyons B et al. Immune-modified response evaluation criteria in solid tumors (imRECIST): refining guidelines to assess the clinical benefit of cancer immunotherapy. J Clin Oncol 2018; 36 (9): 850–858. doi: 10.1200/JCO.2017.75.1644.

7. Haanen JB a. G, Carbonnel F, Robert C et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018; 29 (Suppl 4): iv264–iv266. doi: 10.1093/annonc/mdy162.

8. Fife BT, Bluestone JA. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev 2008; 224: 166–182. doi: 10.1111/j.1600-065X.2008.00662.x.

9. Yearley JH, Gibson C, Yu N et al. PD-L2 expression in human tumors: relevance to anti-PD-1 therapy in cancer. Clin Cancer Res 2017; 23 (12): 3158–3167. doi: 10.1158/1078-0432.CCR-16-1761.

10. Wolchok JD, Saenger Y. The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation. The Oncologist 2008; 13 (S4): 2–9.

11. Lantuejoul S, Sound-Tsao M, Cooper WA et al. PD-L1 testing for lung cancer in 2019: perspective from the IASLC pathology committee. J Thorac Oncol 2020; 15 (4): 499–519. doi: 10.1016/j.jtho.2019.12.107.

12. Garon EB, Rizvi NA, Hui R et al. Pembrolizumab for the treatment of non–small-cell lung cancer. N Engl J Med 2015; 372 (21): 2018–2028. doi: 10.1056/NEJMoa1501824.

13. Alexandrov LB, Nik-Zainal S, Wedge DC et al. Signatures of mutational processes in human cancer. Nature 2013; 500 (7463): 415–421. doi: 10.1038/nature12477.

14. Ma X, Zhang Y, Wang S et al. Predictive value of tumor mutation burden (TMB) with targeted next-generation sequencing in immunocheckpoint inhibitors for non-small cell lung cancer (NSCLC). J Cancer 2021; 12 (2): 584–594. doi: 10.7150/jca.48105.

15. Prelaj A, Tay R, Ferrara R et al. Predictive biomarkers of response for immune checkpoint inhibitors in non- -small-cell lung cancer. Eur J Cancer 2019; 106: 144–159. doi: 10.1016/j.ejca.2018.11.002.

16. Leonetti A, Wever B, Mazzaschi G et al. Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer. Drug Resist Updat 2019; 46: 100644. doi: 10.1016/j.drup.2019.100644.

17. Manegold C, Dingemans A-M, Gray JE et al. The potential of combined immunotherapy and antiangiogenesis for the synergistic treatment of advanced NSCLC. J Thorac Oncol 2017; 12 (2): 194–207. doi: 10.1016/j.jtho.2016.10.003.

18. Chen DS, Hurwitz H. Combinations of bevacizumab with cancer immunotherapy. The Cancer Journal 2018; 24 (4): 193–204. doi: 10.1097/PPO.0000000000000327.

19. Singhi EK, Horn L, Sequist LV et al. Advanced non-small cell lung cancer: sequencing agents in the EGFR-mutated/ALK-rearranged populations. American Society of Clinical Oncology Educational Book 2019; (39): e187–e197. doi: 10.1200/EDBK_237821.

20. Formenti SC, Demaria S. Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst 2013; 105 (4): 256–265. doi: 10.1093/jnci/djs629.

21. Golden EB, Pellicciotta I, Demaria S et al. The convergence of radiation and immunogenic cell death signaling pathways. Front Oncol 2012; 2: 88. doi: 10.3389/fonc.2012.00088.

22. Demaria S, Ng B, Devitt ML et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys 2004; 58 (3): 862–870. doi: 10.1016/j.ijrobp.2003.09.012.

23. Shaverdian N, Lisberg AE, Bornazyan K et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol 2017; 18 (7): 895–903. doi: 10.1016/S1470-2045 (17) 30380-7.

24. Schoenfeld AJ, Hellmann MD. Acquired resistance to immune checkpoint inhibitors. Cancer Cell 2020; 37 (4): 443–455. doi: 10.1016/j.ccell.2020.03.017.

25. Marchetti P, Botticelli A, Ascierto AP et al. Agnostic evaluation of ipilimumab and nivolumab association: a metaanalysis. J Tran Med 2020; 18 (1): 1–7.

26. Rotte A. Combination of CTLA-4 and PD-1 blockers for treatment of cancer. J Exp Clin Cancer Res 2019; 38 (1): 255. doi: 10.1186/s13046-019-1259-z.

27. Passaro A, Attili I, de Marinis F. CheckMate 9LA: broadening treatment options for patients with non-small- -cell lung cancer. Lancet Oncol 2021; 22 (2): 157–159. doi: 10.1016/S1470-2045 (20) 30701-4.

28. Rodriguez-Abreu D, Johnson ML, Hussein MA et al. Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE). JCO 2020; 38 (15_suppl): 9503–9503. doi: 10.1200/JCO.2020.38.15_suppl.9503.

29. Passiglia F, Reale ML, Cetoretta V et al. Immune-Checkpoint Inhibitors Combinations in Metastatic NSCLC: New Options on the Horizon? Immunotargets Ther 2021; 10: 9–26. doi: 10.2147/ITT.S253581.

30. Herbst RS, Baas P, Kim D-W et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. The Lancet 2016; 387 (10027): 1540–1550. doi: 10.1016/S0140-6736 (15) 01281-7.

31. Herbst RS, Garon EB, Kim D-W et al. Long-term follow-up in the KEYNOTE-010 study of pembrolizumab (pembro) for advanced NSCLC, including in patients (pts) who completed 2 years of pembro and pts who received a second course of pembro. Ann Oncol 2018; 29: x42–x43. doi: 10.1093/annonc/mdy511.003.

32. Herbst RS, Garon EB, Kim D-W et al. Long-term outcomes and retreatment among patients with previously treated, programmed death-ligand 1-positive, advanced non-small-cell lung cancer in the KEYNOTE-010 study. JCO 2020; 38 (14): 1580–1590. doi: 10.1200/JCO.19.02446.

33. Reck M, Rodríguez-Abreu D, Robinson AG et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 2016; 375 (19): 1823–1833. doi: 10.1056/NEJMoa1606774.

34. Reck M, Rodríguez-Abreu D, Robinson AG et al. OA14.01 KEYNOTE-024 3-year survival update: pembrolizumab vs platinum-based chemotherapy for advanced non–small-cell lung cancer. J Thorac Oncol 2019; 14 (10): S243. doi: 10.1016/j.jtho.2019.08.483.

35. Keytruda SPC. [online]. Dostupné z: https: //www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_cs.pdf.

36. Mariamidze E, Mezquita L. ESMO20 YO for YO: highlights on metastatic NSCLC-Keynote 024 update. [online]. Available from: https: //www.esmoopen.com/article/S2059-7029 (20) 32887-8/fulltext.

37. Mok TS, Wu Y-L, Kudaba I et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet 2019; 393 (10183): 1819–1830. doi: 10.1016/S0140-6736 (18) 32409-7.

38. Morgensztern D. KEYNOTE-042 and the role for single agent pembrolizumab in patients with PD-L1 tumor proportion score 1-49. J Thorac Dis 2019; 11 (Suppl 15): S1963–S1965. doi: 10.21037/jtd.2019.07.80.

39. Gandhi L, Rodríguez-Abreu D, Gadgeel S et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 2018; 378 (22): 2078–2092. doi: 10.1056/NEJMoa1801005.

40. Gadgeel S, Rodríguez-Abreu D, Speranza G et al. Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer. J Clin Oncol 2020; 38 (14): 1505–1517. doi: 10.1200/JCO.19.03136.

41. Paz-Ares L, Luft A, Vicente D et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med 2018; 379 (21): 2040–2051. doi: 10.1056/NEJMoa1810865.

42. Paz-Ares L, Vicente D, Tafreshi A et al. A randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC: protocol-specified final analysis of KEYNOTE-407. J Thorac Oncol 2020; 15 (10): 1657–1669. doi: 10.1016/j.jtho.2020.06.015.

43. Borghaei H, Paz-Ares L, Horn L et al. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. New Engl J Med 2015; 373 (17): 1627–1639. doi: 10.1056/NEJMoa1507643.

44. Brahmer J, Reckamp KL, Baas P et al. Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer. New Engl J Med 2015; 373 (2): 123–135. doi: 10.1056/NEJMoa1504627.

45. Borghaei H, Brahmer JR, Horn L et al. Nivolumab (nivo) vs docetaxel (doc) in patients (pts) with advanced NSCLC: CheckMate 017/057 2-y update and exploratory cytokine profile analyses. JCO 2016; 34 (15_suppl): 9025–9025. doi: 10.1200/JCO.2016.34.15_suppl.9025.

46. Opdivo SPC. [online]. Dostupné z: https: //www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_cs.pdf.

47. Borghaei H, Gettinger S, Vokes EE et al. Five-year outcomes from the randomized, phase III trials CheckMate 017 and 057: nivolumab versus docetaxel in previously treated non–small-cell lung cancer. J Clin Oncol 2021; 39 (7): 723–733. doi: 10.1200/JCO.20.01605.

48. Paz-Ares L, Brahmer J, Hellmann MD et al. CheckMate 227: a randomized, open-label phase 3 trial of nivolumab, nivolumab plus ipilimumab, or nivolumab plus chemotherapy versus chemotherapy in chemotherapy-naïve patients with advanced non-small cell lung cancer (NSCLC). Ann Oncol 2017; 28: ii50–ii51. doi: 10.1093/annonc/mdx091.064.

49. Hellmann MD, Ciuleanu T-E, Pluzanski A et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med 2018; 378 (22): 2093–2104. doi: 10.1056/NEJMoa1801946.

50. Hellmann MD, Paz-Ares L, Bernabe Caro R et al. Nivolumab plus ipilimumab in advanced non–small-cell lung cancer. N Engl J Med 2019; 381 (21): 2020–2031. doi: 10.1056/NEJMoa1910231.

51. Ramalingam SS, Ciuleanu TE, Pluzanski A et al. Nivolumab + ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: three-year update from CheckMate 227 Part 1. JCO 2020; 38 (15_suppl): 9500–9500. doi: 10.1200/JCO.2020.38.15_suppl.9500.

52. Reck M, Ciuleanu T-E, Dols MC et al. Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA. JCO 2020; 38 (15_suppl): 9501–9501. doi: 10.1200/JCO.2020.38.15_suppl. 9501.

53. Paz-Ares L, Ciuleanu T-E, Cobo M et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol 2021; 22 (2): 198–211. doi: 10.1016/S1470-2045 (20) 30641-0.

54. Rittmeyer A, Barlesi F, Waterkamp D et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. The Lancet 2017; 389 (10066): 255–265. doi: 10.1016/S0140-6736 (16) 32 517-X.

55. Tecentriq SPC. [online]. Dostupné z: https: //www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_cs.pdf.

56. von Pawel J, Bordoni R, Satouchi M et al. Long-term survival in patients with advanced non–small-cell lung cancer treated with atezolizumab versus docetaxel: results from the randomised phase III OAK study. Eur J Cancer 2019; 107: 124–132. doi: 10.1016/j.ejca.2018.11. 020.

57. Mazieres J, Rittmeyer A, Gadgeel S et al. Atezolizumab versus docetaxel in pretreated patients with NSCLC: final results from the randomized phase 2 POPLAR and phase 3 OAK clinical trials. J Thorac Oncol 2021; 16 (1): 140–150. doi: 10.1016/j.jtho.2020.09.022.

58. Herbst RS, Giaccone G, de Marinis F et al. Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC. N Engl J Med 2020; 383 (14): 1328–1339. doi: 10.1056/NEJMoa1917346.

59. Jassem J, Herbst RS, de Marinis F et al. IMpower110: Clinical safety in a phase III study of atezolizumab (atezo) monotherapy (mono) vs platinum-based chemotherapy (chemo) in first-line non-small cell lung cancer (NSCLC). JCO 2020; 38 (15_suppl): e21623–e21623. doi: 10.1200/JCO.2020.38.15_suppl.e21623.

60. Socinski MA, Jotte RM, Cappuzzo F et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med 2018; 378 (24): 2288–2301. doi: 10.1056/NEJMoa1716948.

61. Socinski MA, Mok TS, Nishio M et al. Abstract CT216: IMpower150 final analysis: Efficacy of atezolizumab (atezo) + bevacizumab (bev) and chemotherapy in first-line (1L) metastatic nonsquamous (nsq) non-small cell lung cancer (NSCLC) across key subgroups. Cancer Res 2020; 80 (16_Suppl): CT216–CT216. doi: 10.1158/1538-7445.AM2020-CT216.

62. Reck M, Mok TSK, Nishio M et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir Med 2019; 7 (5): 387–401. doi: 10.1016/S2213-2600 (19) 30084-0.

63. Rizvi NA, Cho BC, Reinmuth N et al. Durvalumab with or without tremelimumab vs standard chemotherapy in first-line treatment of metastatic non-small cell lung cancer: the MYSTIC phase 3 randomized clinical trial. JAMA Oncol 2020; 6 (5): 661–674. doi: 10.1001/jamaoncol.2020.0237.

64. First-line durvalumab improves survival compared to chemotherapy in metastatic NSCLC. [online]. Available from: https: //www.esmo.org/oncology-news/First-line-Durvalumab-Improves-Survival-Compared-to-Chemotherapy-in-Metastatic-NSCLC.

65. Peters S, Cho BC, Reinmuth N et al. Tumor mutational burden (TMB) as a biomarker of survival in metastatic non-small cell lung cancer (mNSCLC): blood and tissue TMB analysis from MYSTIC, a phase III study of first-line durvalumab ± tremelimumab vs chemotherapy. [abstract]. Cancer Res 2019; 79 (13 Suppl): CT074–CT074. doi: 10.1158/1538-7445.AM2019-CT074.

66. Planchard D, Popat S, Kerr K et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2019; 30 (5): 863–870. doi: 10.1093/annonc/mdy474.

67. Antonia SJ, Villegas A, Daniel D et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 2017; 377 (20): 1919–1929. doi: 10.1056/NEJMoa1709937.

68. Gray JE, Villegas A, Daniel D et al. Three-year overall survival with durvalumab after chemoradiotherapy in stage III NSCLC-update from PACIFIC. J Thorac Oncol 2020; 15 (2): 288–293. doi: 10.1016/j.jtho.2019.10.002.

69. Faivre-Finn C, Vicente D, Kurata T et al. LBA49 durvalumab after chemoradiotherapy in stage III NSCLC: 4-year survival update from the phase III PACIFIC trial. Ann Oncol 2020; 31: S1178–S1179. doi: 10.1016/j.annonc.2020.08.2281.

70. Antonia SJ, Villegas A, Daniel D et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med 2018; 379 (24): 2342–2350. doi: 10.1056/NEJMoa1809697.

71. Faivre-Finn C, Spigel DR, Senan S et al. Efficacy and safety evaluation based on time from completion of radiotherapy to randomization with durvalumab or placebo in pts from PACIFIC. Ann Oncol 2018; 29 (suppl_8): viii488–viii492. doi: 10.1093/annonc/mdy291.

72. Antonia SJ, Villegas A, Daniel D et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med 2018; 379 (24): 2342–2350. doi: 10.1056/NEJMoa1809697.

73. Imfinzi SPC. [online]. Dostupné z: https: //www.ema.europa.eu/en/documents/product-information/imfinzi-epar-product-information_cs.pdf.